title: Comparative assessment of the bioavailability, efficacy and safety of a modified-release (MR) carbonyl iron tablet and oral conventional iron preparation in adult Indian patients with nutritional iron deficiency anaemia.
abstract: The objective of the study is to evaluate the bioavailability, efficacy and safety of a new modified-release (MR) formulation of carbonyl iron (45 mg) relative to a commercially available conventional formulation of ferrous fumarate (300 mg) in adult Indian patients with clinical and laboratory diagnosis of nutritional iron deficiency anaemia. This prospective, comparative, randomised, double-blind study was carried out among 60 patients received a single daily dose of either MR carbonyl iron or ferrous fumarate for 12 weeks. The effect of therapy on haematological parameters and iron status and estimation of bioavailability were the main efficacy outcomes. There was a significant (p<0.05) increase in mean haemoglobin levels, reticulocyte counts, haematocrit and mean corpuscular volume in MR carbonyl iron group compared to ferrous fumarate group. There was also an increase in mean serum iron and ferritin levels and a corresponding decrease in total iron binding capacity in MR carbonyl iron group compared to ferrous fumarate group at the end of 12 weeks therapy. The estimated overall bioavailability of MR carbonyl iron was about 147% that of ferrous fumarate. Both the formulations were equally well-tolerated and adverse events were mainly gastrointestinal in nature. The prevalence of adverse events was slightly more in the ferrous fumarate group. It can be concluded that the MR formulation of carbonyl iron was more efficacious than ferrous fumarate in correcting haematologic abnormalities and improving iron status in patients with nutritional iron deficiency anaemia. In conditions where efficacy is an important consideration, the higher bioavailability of MR carbonyl iron may make it the treatment of choice for nutritional iron deficiency anaemia.
authors.affiliation: Glenmark Pharmaceuticals Ltd, Mumbai.
authors.forename: B B
authors.initials: BB
authors.lastname: Adsul
authors.forename: Anish
authors.initials: A
authors.lastname: Desai
authors.forename: Ashish
authors.initials: A
authors.lastname: Gawde
authors.forename: Vidyagauri
authors.initials: V
authors.lastname: Baliga
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D018798:Anemia, Iron-Deficiency / Q000188:drug therapy*; D001682:Biological Availability; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D005260:Female; D005296:Ferrous Compounds / Q000627:therapeutic use*; D006801:Humans; D007501:Iron / Q000627:therapeutic use*; D054354:Iron Carbonyl Compounds; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000627:therapeutic use*
chemical_list: D003692:Delayed-Action Preparations; D005296:Ferrous Compounds; D009942:Organometallic Compounds; D054354:Iron Carbonyl Compounds; D007501:Iron; C031621:ferrous fumarate